(Q42919980)

English

Cabazitaxel

scientific article published on September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Cabazitaxel. (English)

1 reference

Europe PubMed Central

11 November 2017

4

1 reference

Europe PubMed Central

11 November 2017

author name string

Matthew D Galsky

1

1 reference

Europe PubMed Central

11 November 2017

Argyris Dritselis

2

1 reference

Europe PubMed Central

11 November 2017

Peter Kirkpatrick

3

1 reference

Europe PubMed Central

11 November 2017

publication date

1 September 2010

1 reference

Europe PubMed Central

11 November 2017

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

11 November 2017

9

1 reference

Europe PubMed Central

11 November 2017

9

1 reference

Europe PubMed Central

11 November 2017

677-678

1 reference

Europe PubMed Central

11 November 2017

https://scigraph.springernature.com/pub.10.1038/nrd3254

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Microtubules as a target for anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3254

31 March 2020

Identifiers

10.1038/NRD3254

1 reference

Europe PubMed Central

11 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42919980&oldid=2161196689"